Blood Management Solutions: OrthoPAT Advance Device The next-generation OrthoPAT perioperative autotransfusion device, the OrthoPAT Advance which received a 510K approval in Q3 of fiscal 2013, has been designed with new features and capabilities that directly address ease-of-use and other features suggested by customers. This new product offering is on track for limited market release to identified U.S. hospital customers in the first half of fiscal 2014.
Blood Management Solutions:
Emerging Market Growth Investments
The company is committed to increasing investment levels in emerging market growth initiatives, principally in China. Such investments have led to an increase in Haemonetics' employment level in
and rapid acceptance of the company's thromboelastography
("TEG") diagnostic and cell salvage ("Cell Saver Elite") product offerings by key opinion leader surgeons and hospitals in key Chinese provinces. New surgical applications for these products have expanded their served markets.
Planned Hemerus Medical, LLC Acquisition
September 17, 2012
, the company indicated that the U.S. FDA had requested additional information from Hemerus. Hemerus remains on track to provide the required information to the FDA later this month.
Mr. Concannon concluded: "We look forward to discussing these key business initiatives at this year's J.P. Morgan Healthcare Conference. Together they represent exciting growth opportunities and we are confident in their progress. They are the kinds of initiatives our customers expect from the global leader of blood management solutions as they seek ways to reduce costs and improve clinical outcomes."
As previously announced, the public may access Mr. Concannon's presentation live at
and that webcast will be archived and available for approximately 90 days.
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, information technology platforms, and consulting services deliver a suite of business solutions to help our customers improve clinical outcomes and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at
Cautionary / Safe Harbor Language
This release contains forward-looking statements which involve risks and uncertainties, including the approval of new products by regulatory bodies, particularly the U.S. Food and Drug Administration, effects of disruption from the acquisition of the Pall Transfusion Medicine business making it more difficult to maintain relationships with employees, customers, vendors and other business partners, unexpected expenses incurred to integrate the Pall Transfusion Medicine business, the effect of uncertainties in markets outside the U.S. (including
) in which we operate, technological advances in the medical field and standards for transfusion medicine and our ability to successfully implement products that incorporate such advances and standards, product demand, product quality, market acceptance, regulatory uncertainties, the effect of economic and political conditions, the impact of competitive products and pricing, blood product reimbursement policies and practices, foreign currency exchange rates, changes in customers' ordering patterns, the effect of communicable diseases and other risks detailed in the Company's filings with the Securities and Exchange Commission. The foregoing list should not be construed as exhaustive.
Forward-looking statements are based on estimates and assumptions made by management of the Company and are believed to be reasonable, though inherently uncertain and difficult to predict. Actual results and experience could differ materially from the forward-looking statements. Information set forth in this press release is current as of today and the Company undertakes no duty or obligation to update this information.